“…While its prevalence is eclipsed by myeloma and osteosarcoma, it ranks as the third most common primary malignant bone tumor [ [2] , [3] , [4] ]. Its incidence is notably variable, with European rates approximating 1–4 cases per 100,000 individuals [ 3 ]. The male gender exhibits a predilection, with a reported sex ratio of 2:1 [ 3 , 4 ].…”